Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rawat, S.
Right arrow Articles by Swick, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rawat, S.
Right arrow Articles by Swick, H. M.
NEUROLOGY 1981;31:1173
© 1981 American Academy of Neurology

Valproic acid and secondary hyperammonemia

Sumant Rawat, M.B.B.S., Winslow J. Borkowski, Jr., M.D. and Herbert M. Swick, M.D.

Department of Neurology, The Medical College of Wisconsin, Milwaukee, W1.

An 11-year-old girl with complex seizures was started on valproic acid WPA) in addition to clonazepam and ethosux-imide. Shortly thereafter, she developed marked hyperammonemia that was worsened by a protein load. The hyperammonemia improved somewhat when protein was not given, and it resolved on discontinuation of the valproic acid. No associated changes in serum transaminases or bilirubin were observed. Isolated hyperammonemia may occur soon after VPA ingestion and appears to be a relatively infrequent, reversible side effect. The mechanism of hyperammonemia probably differs from other manifestations of hepatotoxicity, such as elevated transaminases or frank hepatic failure.

Address correspondence and reprint requests to Dr. Swick, Associate Professor of Neurology and Pediatrics, Department of Neurology, Medical College of Wisconsin, Milwaukee Children's Hospital, PO Box 1997, Milwaukee, WI 53201.

Accepted for publication December 3, 1980.




This article has been cited by other articles:


Home page
Journal of Pharmacy PracticeHome page
C. A. Ott, N. Campbell, and E. A. Dworek
Valproic Acid Induced Hyperammonemia in a Patient With Schizoaffective Disorder
Journal of Pharmacy Practice, February 1, 2007; 20(1): 82 - 92.
[Abstract] [PDF]


Home page
The Annals of PharmacotherapyHome page
L. Mallet, S. Babin, and J. A Morais
Valproic Acid-Induced Hyperammonemia and Thrombocytopenia in an Elderly Woman
Ann. Pharmacother., October 1, 2004; 38(10): 1643 - 1647.
[Abstract] [Full Text] [PDF]


Home page
J Child NeurolHome page
D. L. Coulter
Carnitine Deficiency in Epilepsy: Risk Factors and Treatment
J Child Neurol, November 1, 1995; 10(2_suppl): 2S32 - 2S39.
[Abstract] [PDF]


Home page
J Child NeurolHome page
D. L. Coulter
Review Article: Carnitine, Valproate, and Toxicity
J Child Neurol, January 1, 1991; 6(1): 7 - 14.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by AAN Enterprises, Inc.